Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06781255 · ClinicalTrials.gov registry record · Phase 1
Evaluation of K9 in Subjects With Diabetic Macular Edema (DME)
A Phase 1 study of Diabetic Macular Edema, sponsored by Michelle Abou-Jaoude.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 5
- Enrollment target
- 1
- Study location
NCT06781255 is a Phase 1 study of Diabetic Macular Edema that is actively recruiting participants, run by Michelle Abou-Jaoude. The registered enrollment target is 5 participants, below the 3,794-participant average among 63 other Diabetic Macular Edema trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06781255, a Phase 1 study of Diabetic Macular Edema, is actively recruiting participants, sponsored by Michelle Abou-Jaoude.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 5 participants
- Enrollment target
- 1
- Study location
Study Summary
A non-randomized study evaluating the safety of an orally administered inflammasome inhibitor, K9, for the treatment of diabetic macular edema (DME).
Conditions Studied
Interventions
- DRUG Kamuvudine-9
Study Locations (1)
Kentucky
- University of Kentucky - Lexington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2025-03-13 |
| Est. Completion | 2027-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06781255
The ClinicalTrials.gov registry entry for NCT06781255 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,794-participant average among 63 other Diabetic Macular Edema trials with a reported enrollment target (100% lower). The listed sponsor is Michelle Abou-Jaoude, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Diabetic Macular Edema appearing as the primary indexed condition, and to 1 intervention - of which Kamuvudine-9 is the first listed.
NCT06781255 reports 1 study location spanning 1 distinct geographic area - top geographies include Kentucky.
Frequently Asked Questions
What is clinical trial NCT06781255 about?
NCT06781255 is a clinical study titled "Evaluation of K9 in Subjects With Diabetic Macular Edema (DME)". A non-randomized study evaluating the safety of an orally administered inflammasome inhibitor, K9, for the treatment of diabetic macular edema (DME).
What is the current status of trial NCT06781255?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 5 participants. The study started on 2025-03-13. Estimated completion is 2027-07.
What conditions does trial NCT06781255 study?
This clinical trial studies the following conditions: Diabetic Macular Edema.
What interventions are being tested in trial NCT06781255?
The interventions under investigation include: Kamuvudine-9 (DRUG).
Who is sponsoring clinical trial NCT06781255?
This trial is sponsored by Michelle Abou-Jaoude, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06781255 being conducted?
This trial has 1 study location across Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetic Macular Edema
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
EC-104 Intravitreal Implant for the Treatment of Diabetic Macular Edema
RECRUITING · Phase 1
-
Phase I Study to Assess the Safety and Efficacy of OCU200 for Center-Involved Diabetic Macular Edema (DME)
RECRUITING · Phase 1
-
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7446603 Administered Alone or in Combination With Aflibercept or Faricimab in Participants With Diabetic Macular Edema
RECRUITING · Phase 1
-
Kamuvudine-9 (K9) in Diabetic Macular Edema
RECRUITING · Phase 1
-
A Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of RO7823653 in Participants With Diabetic Macular Edema (DME)
RECRUITING · Phase 1
-
A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7497372 in Participants With Diabetic Macular Edema (DME)
ACTIVE NOT RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.